Susan D. Wyrick - Mar 6, 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Acting Chief Financial Officer and Principal Accounting Officer
Signature
/s/ Bernard J. Cassidy, Attorney-in-Fact for Susan D. Wyrick
Stock symbol
SANA
Transactions as of
Mar 6, 2025
Transactions value $
-$2,140
Form type
4
Date filed
3/10/2025, 08:13 PM
Previous filing
Mar 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Options Exercise $0 +3.25K +2.1% $0.00 158K Mar 7, 2025 Direct
transaction SANA Common Stock Tax liability -$2.14K -836 -0.53% $2.56 157K Mar 10, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Award $0 +41.7K $0.00 41.7K Mar 6, 2025 Common Stock 41.7K Direct F1, F2
transaction SANA Stock Option (Right to Buy) Award $0 +188K $0.00 188K Mar 6, 2025 Common Stock 188K $2.55 Direct F3
transaction SANA Restricted Stock Units Options Exercise $0 -3.25K -25% $0.00 9.75K Mar 7, 2025 Common Stock 3.25K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F4 The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer